CRUK

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies

Retrieved on: 
Monday, November 27, 2023
Drug resistance, UKRI, Cellular senescence, Metastasis, Nature Cell Biology, Protein, Medicine, ICS, Research, Chemical biology, Imperial College London, Spacecraft, COPI, CRUK, NMT, ARF1, Cancer, GSK, Notifiable disease, Laboratory, Inflammation, Cell, Phenotype, Medical school, Data, ADC, Francis Crick Institute

Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.

Key Points: 
  • Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.
  • Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.
  • Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells.
  • Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023
Drug development, Survival, NHS foundation trust, Research, The Royal Marsden NHS Foundation Trust, Half-life, ESMO, Infrared spectroscopy correlation table, Institute of Cancer Research, DCR, Pharmacokinetics, Prostate cancer, CRUK, HER3, Clinical trial, Biology, Cancer, NRG1, The Institute, Interim, Cancer research, Pancreatic cancer, Oncology, Safety, European Society for Medical Oncology, The Christie NHS Foundation Trust, Royal Marsden Hospital, Cancer Research UK, Patient, Pharmaceutical industry, Phase

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023
Drug development, Survival, NHS foundation trust, Research, The Royal Marsden NHS Foundation Trust, Half-life, ESMO, Infrared spectroscopy correlation table, Institute of Cancer Research, DCR, Pharmacokinetics, Prostate cancer, CRUK, HER3, Clinical trial, Biology, Cancer, NRG1, The Institute, Interim, Cancer research, Pancreatic cancer, Oncology, Safety, European Society for Medical Oncology, The Christie NHS Foundation Trust, Royal Marsden Hospital, Cancer Research UK, Patient, Pharmaceutical industry, Phase

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Hospitals, Other Health, National Academy of Medicine, Acute myeloid leukemia, Doctor of Philosophy, Memorial Sloan Kettering Cancer Center, Research, Francis Crick Institute, Bristol Myers Squibb, Harvard University, NAM, The Emperor of All Maladies, Cell biology, Medicine, National academy, Pulitzer Prize, Therapy, Immunotherapy, Genetics, Mukherjee, Assistant, Dana–Farber Cancer Institute, ARD International Music Competition, CRUK, Disease, Dana, National Academy of Science and Technology, Tony Faeth, Pharmaceutical industry

Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).

Key Points: 
  • Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).
  • "Dr. Mukherjee's induction into the National Academy of Medicine reaffirms Faeth Therapeutics' dedication to unparalleled scientific rigor and innovation.
  • In the National Academy of Medicine, members are elected by their colleagues as a testament to their exceptional accomplishments.
  • Being inducted into the academy represents one of the most prestigious accolades within the realm of medicine.

Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research

Retrieved on: 
Tuesday, July 18, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, Maintenance, Twist Bioscience, Therapy, Doctor of Philosophy, Martek Biosciences Corporation, Cancer, Cancer Research UK, Multimedia, Therapeutic Innovation & Regulatory Science, CRUK, Organization, Patient, Collection, Twist, Silicon, Pharmaceutical industry, Library

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation engine at the core of one of the world’s largest private funders of cancer research, Cancer Research UK (CRUK), today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation engine at the core of one of the world’s largest private funders of cancer research, Cancer Research UK (CRUK), today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230718140133/en/
    “Teaming up with Cancer Research Horizons to support exploratory drug discovery efforts, validating and de-risking biological targets has the potential to be groundbreaking for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.

World’s Largest Independent Health Agency Opens in Asia-Pacific

Retrieved on: 
Wednesday, June 14, 2023
Health, Commercial Building & Real Estate, Other Science, Construction & Property, General Health, Research, Science, Accreditation, Marketing, UOB, Partner (business rank), Macdonald, CRUK, Omnicom Group, Patient, Advertising, FMCG, Coca-Cola, News, Wellness, Y&R, Clio Awards, Cannes Lions International Festival of Creativity, NAFA, Drug discovery, Diagnosis, New York Festivals, D, MTV Youth Icon of the Year, Everest Link, Radiopharmaceutical, Creativity, Colgate, Mastercard, Fame, ADS, LG, Mitchell, The One Show, McCann, CAAS, Molecular imaging, Ford, Nanyang Academy of Fine Arts, Art, Physician, Hall, OTC, LATAM, Film industry, Management, Nursing, Click, Ogilvy, Shraddha, Effie Ellis, Adidas

Klick Health today announced it has opened an Asia-Pacific hub in Singapore, headed up by veteran agency executives Mitchell Tan, Dr. Shraddha Tawate, Dr. Nevil Chamin, and Alvin Yeo.

Key Points: 
  • Klick Health today announced it has opened an Asia-Pacific hub in Singapore, headed up by veteran agency executives Mitchell Tan, Dr. Shraddha Tawate, Dr. Nevil Chamin, and Alvin Yeo.
  • Klick Health CEO Lori Grant said, “We are extremely excited to have opened our doors in Singapore as we continue our global expansion.
  • She joins Klick with a proven track record in developing impactful and commercially effective strategies for biosciences, consumer healthcare, healthcare services, medical devices, pharmaceuticals, and public health organization brands.
  • Tawate has served as an Effies (India) Health and Wellness jury member and her work has been recognized by global creativity and effectiveness authorities, including Cannes Lions and Clio Health awards.

AI Tools are Enhancing Inclusivity and Reducing Bias in Hiring Processes

Retrieved on: 
Tuesday, May 9, 2023
PDN, Natural language processing, Analytics, Communication, Partnership, Probability, Original equipment manufacturer, ChatGPT, Street, Intelligence, Holding, Uniloc USA, Inc. v. Microsoft Corp., OpenAI, SOC, Language, CV22, CRUK, Spondias dulcis, Acquisition, Machine learning, Innodata, Drug discovery, Artificial intelligence, Diagnosis, Growth, Neoplasm, AI, BBAI, ADAS, Transport, Fraud, Bias, News, NYSE, Financial News, Total, Automation, Cryptocurrency, Sales, Online shopping, Glutaminase

NEW YORK, May 9, 2023 /PRNewswire/ -- Artificial intelligence (AI) has rapidly evolved over the last decade. With advancements in machine learning, natural language processing, and computer vision, AI is revolutionizing the way we interact with technology and each other. One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI. With its advanced natural language processing capabilities, ChatGPT can understand human language and generate human-like responses, making it an ideal tool for customer service, virtual assistants, and chatbots. The impact of AI is already being felt across various industries, from healthcare and finance to transportation and manufacturing. For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans. In finance, AI is being used to detect fraud, predict market trends, and optimize investment strategies. Professional Diversity Network, Inc. (NASDAQ: IPDN), Innodata Inc. (NASDAQ: INOD), Ambarella, Inc. (NASDAQ: AMBA), BigBear.ai Holdings, Inc. (NYSE: BBAI), Predictive Oncology Inc. (NASDAQ: POAI)

Key Points: 
  • One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI.
  • For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans.
  • AI tools, on the other hand, can analyze large amounts of data without being influenced by personal biases.
  • Moreover, fraud detection AI tools can help companies identify and eliminate fake resumes and fraudulent job applications.

AI Tools are Enhancing Inclusivity and Reducing Bias in Hiring Processes

Retrieved on: 
Tuesday, May 9, 2023
PDN, Natural language processing, Analytics, Communication, Partnership, Probability, Original equipment manufacturer, ChatGPT, Street, Intelligence, Holding, Uniloc USA, Inc. v. Microsoft Corp., OpenAI, SOC, Language, CV22, CRUK, Spondias dulcis, Acquisition, Machine learning, Innodata, Drug discovery, Artificial intelligence, Diagnosis, Growth, Neoplasm, AI, BBAI, ADAS, Transport, Fraud, Bias, News, NYSE, Financial News, Total, Automation, Cryptocurrency, Sales, Online shopping, Glutaminase

NEW YORK, May 9, 2023 /PRNewswire/ -- Artificial intelligence (AI) has rapidly evolved over the last decade. With advancements in machine learning, natural language processing, and computer vision, AI is revolutionizing the way we interact with technology and each other. One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI. With its advanced natural language processing capabilities, ChatGPT can understand human language and generate human-like responses, making it an ideal tool for customer service, virtual assistants, and chatbots. The impact of AI is already being felt across various industries, from healthcare and finance to transportation and manufacturing. For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans. In finance, AI is being used to detect fraud, predict market trends, and optimize investment strategies. Professional Diversity Network, Inc. (NASDAQ: IPDN), Innodata Inc. (NASDAQ: INOD), Ambarella, Inc. (NASDAQ: AMBA), BigBear.ai Holdings, Inc. (NYSE: BBAI), Predictive Oncology Inc. (NASDAQ: POAI)

Key Points: 
  • One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI.
  • For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans.
  • AI tools, on the other hand, can analyze large amounts of data without being influenced by personal biases.
  • Moreover, fraud detection AI tools can help companies identify and eliminate fake resumes and fraudulent job applications.

Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

Retrieved on: 
Thursday, March 23, 2023
AACR, Mayo Clinic, University, Education, Cancer research, American Society of Clinical Oncology, GSK-3, United States Air Force Scientific Advisory Board, MD Anderson Cancer Center, Doctor of Philosophy, CRUK, NAC, ASCO, Organization, DO, Food and Drug Administration Amendments Act of 2007, Patient, Clinical professor, American Association for Cancer Research, FDA, Therapy, Society, Food, Pharmaceutical industry, Actuate

CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.
  • “We congratulate Dr. LoRusso for being elected to lead the AACR and for her significant contributions to the field of cancer research and therapeutic development,” said Daniel M. Schmitt, President & CEO of Actuate.
  • “As a founding member of Actuate’s Scientific Advisory Board, Dr. LoRusso has played an invaluable role in designing the innovative accelerated clinical development plans for elraglusib, Actuate’s best-in-class agent, for the benefit of adult and pediatric patients with difficult-to-treat cancers.”
    Dr. LoRusso joined the Actuate Scientific Advisory Board in October 2015.
  • She also has worked closely with Cancer Research United Kingdom (CRUK), as the chair of their New Agents Committee (NAC).

Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

Retrieved on: 
Thursday, March 23, 2023
AACR, Mayo Clinic, University, Education, Cancer research, American Society of Clinical Oncology, GSK-3, United States Air Force Scientific Advisory Board, MD Anderson Cancer Center, Doctor of Philosophy, CRUK, NAC, ASCO, Organization, DO, Food and Drug Administration Amendments Act of 2007, Patient, Clinical professor, American Association for Cancer Research, FDA, Therapy, Society, Food, Pharmaceutical industry, Actuate

CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.
  • “We congratulate Dr. Russo for being elected to lead the AACR and for her significant contributions to the field of cancer research and therapeutic development” said Daniel M. Schmitt, President & CEO of Actuate.
  • Dr. LoRusso has served in leadership positions of several other organizations, including the education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop.
  • She also has worked closely with Cancer Research United Kingdom (CRUK), as the chair of their New Agents Committee (NAC).